Braintree Labs Hit With Antitrust Suit Over MiraLax

Law360, New York (March 13, 2007, 12:00 AM EDT) -- A New York drug cooperative has filed a proposed class action against Braintree Laboratories Inc., accusing the drug maker of conspiring to block rivals from marketing a generic version of its laxative MiraLax and improperly listing a patent with the U.S. Patent and Trademark Office.

The lawsuit, filed Monday by Rochester Drug Co-Operative Inc. in the U.S. District Court for the District of Delaware, alleges that Braintree’s anti-competitive scheme allowed it to charge supracompetitive prices for MiraLax, or polyethylene glycol 3350, an osmotic laxative that causes...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.